Table 3.
Protective Effects of Statins
| Eventa | Number of Beneficiaries Included in the Analysis (N) | Number of Beneficiaries with Incident Event (N) | Hazard Ratio [95% Confidence Interval] per Month of Statin Use p-Value | Percentage Decreased Hazard of Developing Event per Month of Medication Use | Hazard Ratio [95% Confidence Interval] per Year of Statin Use p-Value | Decreased Risk of Event With One Year of Continuous Statin Useb | Hazard Ratio [95% Confidence Interval] per Two-Years of Statin Use p-Value | Decreased Risk of Event With Two Years of Continuous Statin Usec |
|---|---|---|---|---|---|---|---|---|
| New Diagnosis of OAG | 241,711 | 10,266 | 0.997 [0.994–0.999]d p =0.0056 |
0.3% | 0.960 [0.933–0.988]d p =0.0056 |
4% | 0.922 [0.870–0.976]d p =0.0056 |
8% |
| Conversion from Suspected Glaucoma to OAG | 49,628 | 6.934 | 0.996 [0.993–0.999] p = 0.0062 |
0.4% | 0.952 [0.920–0.986] p = 0.0062 |
5% | 0.907 [0.846–0.973] p = 0.0062 |
9% |
| New Prescription of IOP Lowering Medication | 241,251 | 11,420 | 0.996 [0.993–0.998] p = 0.0002 |
0.4% | 0.950 [0.924–0.976] p = 0.0002 |
5% | 0.902 [0.854–0.953] p = 0.0002 |
10% |
| Need for Glaucoma Laser or Incisional Surgery | 8,236 | 1,009 | 1.002 [0.994–1.010] p = 0.6811, NS |
1.021 [0.925–1.127] p = 0.6811, NS |
1.042 [0.856–1.269] p = 0.6811, NS |
a
Those diagnosed with the event during the two-year look-back period were excluded to exclude non-incident cases.
b
Reference group: Patients not on statins at all in the past year.
c
Reference group: Patients not on statins at all in the past two years.
d
For example, a Hazard Ratio of 0.996 means a 0.4% decreased risk of developing OAG with every additional month of statin use.
NS = non-significant, IOP = intraocular pressure, OAG = open-angle glaucoma